Current Drug Targets

Francis J. Castellino
Kleiderer-Pezold Professor of Biochemistry
Director, W.M. Keck Center for Transgene Research
Dean Emeritus, College of Science
230 Raclin-Carmichael Hall, University of Notre Dame
Notre Dame, IN 46556


β-Sheet Breakers for Alzheimers Disease Therapy

Author(s): Bieler S. and Soto C.

Affiliation: Protein Misfolding Disorders Laboratory, Department of Neurology, University of Texas Medical Branch,Galveston, TX, USA


A growing wealth of evidence indicates that the key pathological event in Alzheimers disease is the conversion of the normal soluble amyloid-β peptide into β-sheet-rich oligomeric structures which have a neurotoxic activity and ability to form insoluble amyloid deposits that accumulate in the brain. b-sheet breakers constitute a new class of drugs that are designed to specifically bind amyloid-β peptide and block and / or reverse this abnormal conformational change. In this article we review this approach, describe diverse compounds reported to have this activity and summarize the data supporting the view that b-sheet breakers could be serious candidates to combat this devastating disease.

Keywords: alzheimer disease, amyloid, therapy

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Page: [553 - 558]
Pages: 6
DOI: 10.2174/1389450043345290